Combination treatment in M1 prostate cancer
โ Scribed by P. Ferrari; G. Castagnetti; G. Ferrari; C. A. Pollastri; F. Tavoni; A. Dotti
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 558 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer
BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CaP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR
The legitimate role of radical prostatectomy remains controversial. A prospective study was started at the Mayo Clinic in 1950 to evaluate therapeutic usefulness of the operation. Rigid criteria were established for selection of surgical candidates. From 1950 through 1972, 264 patients had radical p